By marketing “misinformation,” drug companies may scare consumers away from lower-cost generic equivalent drugs, which not only inflates prescription drug spend but also hurts patients.

Read the full article here:

https://www.washingtonpost.com/business/economy/drugmakers-alleged-scare-tactics-may-hold-back-competition/2019/01/09/612ac994-046d-11e9-9122-82e98f91ee6f_story.html?utm_term=.6ffa41507d08